DIAMEDICA THERAPEUTICS INC (DMAC)
Health Care · Clinical-stage biopharmaceutical / cardiovascular and neurological therapeutics · NASDAQ
A clinical-stage biopharmaceutical company developing DM199, a recombinant human kallikrein-1 protein, to treat acute ischemic stroke, preeclampsia, and fetal growth restriction.
What DIAMEDICA THERAPEUTICS INC does
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on severe ischemic disease. Its lead candidate DM199 (rinvecalinase alfa) is the first recombinant synthetic form of human tissue kallikrein-1 (rhKLK1) being clinically studied in patients; it has received Fast Track Designation from the FDA for acute ischemic stroke treatment. The company is conducting Phase 2 studies in preeclampsia and fetal growth restriction in South Africa, Canada, and the UK, and a Phase 2/3 adaptive trial (ReMEDy2) for acute ischemic stroke globally. DM199 is designed to enhance endothelial health, microcirculatory blood flow, and tissue perfusion by increasing nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor production.
Themes: ["acute ischemic stroke (AIS)","preeclampsia / fetal growth restriction","cardiovascular / cerebrovascular disease","tissue kallikrein-based therapy"]
Fundamentals
- Price$7.71 as of 2026-07-09 close
- Market cap$417M as of 2026-07-10
- 1-year return+118.1% as of 2026-07-09 close
- Net margin-1146.8% as of 2026-07-10
- ROE-77.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.96 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: DM199 is in early-to-mid stage clinical trials; FDA requested additional non-clinical embryo-fetal development studies in a rabbit model, and preliminary results suggest antibody response in animals, potentially delaying or complicating US regulatory pathway","Competitive and rapidly-changing environment with unpredictable emerging risks; company is unprofitable with significant accumulated deficit and limited cash runway","Regulatory and safety uncertainty: the company is developing a humanized recombinant protein with limited human safety data; regulatory approvals for preeclampsia and acute ischemic stroke are uncertain and may require substantial additional clinical evidence"]
Competitors & peers
- Genzyme Corporation (gene/cell therapies)
- Neuralstem (neural regeneration)
- Genoptix (molecular diagnostics)
- Medtronic (stroke intervention devices)
- Stryker (neurovascular solutions)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.